A new study reported by Managed Healthcare Executive concludes that patients with atopic dermatitis (chronic eczema characterized by impaired skin-barrier function) face an elevated risk of shingles, the reactivation of varicella-zoster virus that causes herpes zoster. The finding adds a second infectious complication to a disease already associated with recurrent skin infections, and it does so on top of an existing burden of allergy-related comorbidities.

The headline claim is concrete: atopic dermatitis increases shingles risk. What the summary of the study does not state is equally important for clinicians weighing practice change. The circulated report gives no effect size, no hazard ratio, and no absolute risk figures, so the magnitude of the association remains unspecified in the available coverage.

Why might ecema predispose to shingles?

The biological rationale is plausible and well documented in prior literature. Atopic dermatitis compromises the epidermal barrier and skews immune regulation toward type 2 inflammation, which can weaken surveillance of latent viruses. Patients are also more likely to use topical corticosteroids or systemic immunosuppressants, both of which have been linked in earlier research to varicella-zoster reactivation.

The new study appears to confirm that constellation in a defined cohort. However, without access to the study design — whether it was a cohort study, a case-control analysis, or a claims-database review — causality cannot be assumed. Association between a chronic inflammatory disease and a viral reactivation is compatible with several mechanisms, including treatment exposure rather than the disease itself.

What does this mean for dermatology practice?

For clinicians, the immediate question is vaccination. Recombinant zoster vaccine is indicated for adults over 50 in most jurisdictions, and immunocompromised patients may qualify earlier. If the study's risk elevation holds across age groups, dermatologists managing moderate-to-severe atopic dermatitis may need to flag herpes zoster vaccination status during routine review of systemic therapy.

Payers will read the same data differently. An comorbidity signal of this kind typically feeds risk-adjustment models and utilization reviews, and managed-care formularies may face questions about covering zoster vaccination in younger atopic dermatitis patients on immunosuppressive therapy.

What the report leaves open

Three gaps stand out before the finding can be translated into guidance.

• No reported effect size or confidence interval in the available summary.
• No stratification by disease severity or treatment exposure.
• No statement of whether the risk persists after adjusting for age and immunosuppressant use.

Each gap is the kind that a peer-reviewed publication would close; the summary circulating now does not.

Dermatologists should treat the result as a hypothesis-reinforcing signal rather than a practice-changing verdict until the full dataset, including cohort size and adjustment strategy, becomes available. If the association survives adjustment for treatment exposure, expect herpes zoster risk to enter the comorbidity checklists for atopic dermatitis within the next guideline cycle.